An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer

• Conditions: Prostatic Neoplasms

• Registration Number: NCT03523338
• Lead Sponsor: Aragon Pharmaceuticals, Inc.

Brief Summary

The purpose of this study is to collect additional safety data until apalutamide is commercially available for participants with non-metastatic castrate-resistant prostate cancer (NM-CRPC).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-05-01
• Study First Submitted QC: 2018-05-01
• Study First Posted: 2018-05-14
• Status Verified: 2023-12
• Last Update Submitted: 2023-12-07
• Last Update Posted: 2023-12-13

Recruitment & Eligibility

• Status: NO_LONGER_AVAILABLE
• Sex: Male
• Target Recruitment: Not specified

Inclusion Criteria

• Participants with confirmed prostate cancer, with evidence of castration resistance, with a rising prostate-specific antigen (PSA) while on androgen deprivation therapy (ADT), and for whom the treating physician believes additional therapy is indicated in the non-metastatic castrate-resistant prostate cancer (NM-CRPC) setting

  a) Willingness to continue gonadotropin releasing hormone analog (GnRHa) throughout study if the participant is medically castrated

• Must sign an informed consent form (ICF) (or the participant's legally acceptable representative must sign) indicating that the participant understands the purpose of, and procedures required for, the study and is willing to participate in the study

• To avoid risk of drug exposure through the ejaculate (even participants with vasectomies), participants must use a condom during sexual activity while on study drug and for 3 months following the last dose of study drug. Donation of sperm is not allowed while on study drug and for 3 months following the last dose of study drug

• Willingness and ability to comply with prohibitions and restrictions specified in this protocol, scheduled visits, treatment plans, laboratory, and other study procedures, including ability to swallow study drug tablets

Exclusion Criteria

• Previously enrolled in another apalutamide study or eligible for enrollment in another ongoing clinical study of apalutamide
• Enrolled in another interventional clinical study of anti-neoplastic agents
• Ongoing grade greater than (>) 1 acute toxicity due to prior therapy or surgical procedure
• Concurrent therapy with medications known to lower the seizure threshold must have been discontinued or substituted at least 4 weeks prior to study entry
• Current or prior treatment with anti-epileptic medications for the treatment of seizures. History of seizure or condition that may predispose to seizure (including, but not limited to prior cerebrovascular accident, transient ischemic attack, or loss of consciousness within 1 year prior to randomization; brain arteriovenous malformation; or intracranial masses such as a schwannoma or meningioma that is causing edema or mass effect)

Study & Design

• Study Type: EXPANDED_ACCESS
• Study Design: Not specified

Trial Locations

Locations (12)

Ynova Pesquisa Clinica; 🇧🇷 Florianopolis, Brazil

Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo; 🇧🇷 Sao Paulo, Brazil

Fundacao Antonio Prudente - A.C. Camargo Cancer Center; 🇧🇷 Sao Paulo, Brazil

Núcleo de Pesquisa São Camilo; 🇧🇷 São Paulo, Brazil

Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI); 🇧🇷 Rio de Janeiro, Brazil

Ensino e Terapia de Inovacao Clinica AMO - Etica; 🇧🇷 Salvador, Brazil

Hospital Pablo Tobon Uribe; 🇨🇴 Medellin, Colombia

Instituto Nacional de Cancerologia; 🇲🇽 Mexico, Mexico

i Can Oncology Center; 🇲🇽 Monterrey, Mexico

Centro Oncologico Estatal ISSEMYM; 🇲🇽 Toluca, Mexico

Oncologia Integral Satelite; 🇲🇽 Naucalpan, Mexico

Farmaco Oncología especializada S.A. de C.V; 🇲🇽 Zapopan, Mexico